Unknown

Dataset Information

0

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.


ABSTRACT: This phase III randomized trial (ClinicalTrials.gov identifier: NCT00337103) compared eribulin with capecitabine in patients with locally advanced or metastatic breast cancer (MBC).Women with MBC who had received prior anthracycline- and taxane-based therapy were randomly assigned to receive eribulin or capecitabine as their first-, second-, or third-line chemotherapy for advanced/metastatic disease. Stratification factors were human epidermal growth factor receptor-2 (HER2) status and geographic region. Coprimary end points were overall survival (OS) and progression-free survival (PFS).Median OS times for eribulin (n = 554) and capecitabine (n = 548) were 15.9 and 14.5 months, respectively (hazard ratio [HR], 0.88; 95% CI, 0.77 to 1.00; P = .056). Median PFS times for eribulin and capecitabine were 4.1 and 4.2 months, respectively (HR, 1.08; 95% CI, 0.93 to 1.25; P = .30). Objective response rates were 11.0% for eribulin and 11.5% for capecitabine. Global health status and overall quality-of-life scores over time were similar in the treatment arms. Both treatments had manageable safety profiles consistent with their known adverse effects; most adverse events were grade 1 or 2.In this phase III study, eribulin was not shown to be superior to capecitabine with regard to OS or PFS.

SUBMITTER: Kaufman PA 

PROVIDER: S-EPMC4463422 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.

Kaufman Peter A PA   Awada Ahmad A   Twelves Chris C   Yelle Louise L   Perez Edith A EA   Velikova Galina G   Olivo Martin S MS   He Yi Y   Dutcus Corina E CE   Cortes Javier J  

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20150120 6


<h4>Purpose</h4>This phase III randomized trial (ClinicalTrials.gov identifier: NCT00337103) compared eribulin with capecitabine in patients with locally advanced or metastatic breast cancer (MBC).<h4>Patients and methods</h4>Women with MBC who had received prior anthracycline- and taxane-based therapy were randomly assigned to receive eribulin or capecitabine as their first-, second-, or third-line chemotherapy for advanced/metastatic disease. Stratification factors were human epidermal growth  ...[more]

Similar Datasets

| S-EPMC6333992 | biostudies-literature
| S-EPMC6685628 | biostudies-literature
| S-EPMC2903325 | biostudies-literature
| S-EPMC4661183 | biostudies-literature
| S-EPMC4927108 | biostudies-literature
| S-EPMC6461928 | biostudies-literature
| S-EPMC3288403 | biostudies-literature
| S-EPMC8461541 | biostudies-literature
| S-EPMC3179720 | biostudies-literature
| S-EPMC7206765 | biostudies-literature